Galectin Therapeutics, Inc. (GALT)
3.90
+0.14
(+3.72%)
USD |
NASDAQ |
Oct 02, 16:00
3.85
-0.05
(-1.28%)
After-Hours: 20:00
Galectin Therapeutics EPS Diluted (Quarterly) : -0.1393 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1393 |
| March 31, 2026 | -0.077 |
| December 31, 2025 | -0.0853 |
| September 30, 2025 | -0.1281 |
| June 30, 2025 | -0.1195 |
| March 31, 2025 | -0.152 |
| December 31, 2024 | -0.1917 |
| September 30, 2024 | -0.1804 |
| June 30, 2024 | -0.1998 |
| March 31, 2024 | -0.1855 |
| December 31, 2023 | -0.1626 |
| September 30, 2023 | -0.2352 |
| June 30, 2023 | -0.154 |
| March 31, 2023 | -0.1938 |
| December 31, 2022 | -0.18 |
| September 30, 2022 | -0.1445 |
| June 30, 2022 | -0.1629 |
| March 31, 2022 | -0.1671 |
| December 31, 2021 | -0.1228 |
| September 30, 2021 | -0.1443 |
| June 30, 2021 | -0.146 |
| March 31, 2021 | -0.111 |
| December 31, 2020 | -0.1387 |
| September 30, 2020 | -0.1044 |
| June 30, 2020 | -0.1084 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.0623 |
| December 31, 2019 | -0.0914 |
| September 30, 2019 | -0.0498 |
| June 30, 2019 | -0.0609 |
| March 31, 2019 | -0.0549 |
| December 31, 2018 | -0.0813 |
| September 30, 2018 | -0.0744 |
| June 30, 2018 | -0.1075 |
| March 31, 2018 | -0.1218 |
| December 31, 2017 | -0.0779 |
| September 30, 2017 | -0.13 |
| June 30, 2017 | -0.14 |
| March 31, 2017 | -0.15 |
| December 31, 2016 | -0.12 |
| September 30, 2016 | -0.16 |
| June 30, 2016 | -0.20 |
| March 31, 2016 | -0.24 |
| December 31, 2015 | -0.19 |
| September 30, 2015 | -0.26 |
| June 30, 2015 | -0.21 |
| March 31, 2015 | -0.22 |
| December 31, 2014 | -0.1781 |
| September 30, 2014 | -0.17 |
| June 30, 2014 | -0.17 |
| March 31, 2014 | -0.27 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | -1.061 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.113M |
| Total Expenses (Quarterly) | 9.113M |
| Enterprise Value | 385.31M |
| Earnings Yield | -11.02% |
| Normalized Earnings Yield | -9.749 |